{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:32:03Z","timestamp":1790757123922,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Over the past century, classical Hodgkin lymphoma (HL) has been transformed from a uniformly fatal disease to one of the most curable cancers. Given the high cure rate, a major focus of classical HL management is reducing the use of radiation therapy (RT) and chemotherapy agents such as procarbazine and doxorubicin to minimize long\u2010term toxicities. In both North America and Europe, an important philosophy in the management of classical HL is to guide the intensity of treatment according to the risk category of the disease. The main factors used for risk classification are tumor stage, bulk of disease, and the presence of B symptoms. Response to chemotherapy is an important factor guiding the utilization of RT in ongoing Children's Oncology Group (COG) and European Network Pediatric Hodgkin Lymphoma (EuroNet\u2010PHL) trials. Both trial groups have transitioned to reduced RT volumes that target the highest risk sites using highly conformal techniques, along with standard or intensified chemotherapy regimens to improve outcomes in higher risk patients. However, given the potential acute toxicities of intensified chemotherapy, immunoregulatory drugs are being investigated in upcoming trials. The purpose of this review is to summarize current approaches to treating pediatric classical HL according to the COG and EuroNet\u2010PHL.<\/jats:p>","DOI":"10.1002\/pbc.28562","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T11:12:32Z","timestamp":1617621152000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pediatric classical Hodgkin lymphoma"],"prefix":"10.1002","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3253-1071","authenticated-orcid":false,"given":"Andrea C.","family":"Lo","sequence":"first","affiliation":[{"name":"Radiation Oncology British Columbia Cancer and University of British Columbia  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dieckmann","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department of Radiotherapy Medical University Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Pelz","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy Faculty of Medicine Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Gallop\u2010Evans","sequence":"additional","affiliation":[{"name":"Velindre Cancer Centre  Cardiff Wales UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Engenhart\u2010Cabillic","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy University Medical Center Giessen\u2010Marburg  Marburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Vordermark","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy Faculty of Medicine Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Roswell Park Comprehensive Cancer Center, and University of Buffalo Jacobs School of Medicine and Biomedical Sciences  Buffalo New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy L.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology Department of Pediatrics Medical College of Wisconsin Wisconsin  Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis S.","family":"Constine","sequence":"additional","affiliation":[{"name":"Radiation Oncology and Pediatrics University of Rochester Medical Center  Rochester New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Roberts","sequence":"additional","affiliation":[{"name":"Radiation Oncology Yale University  New Haven Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4687-4582","authenticated-orcid":false,"given":"David","family":"Hodgson","sequence":"additional","affiliation":[{"name":"Radiation Oncology Princess Margaret Cancer Center and University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.5410"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184143"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31519"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.07.015"},{"key":"e_1_2_6_6_1","first-page":"1","article-title":"A comparative evaluation of normal tissue doses for patients receiving radiation therapy for Hodgkin lymphoma on the childhood cancer survivor study and recent Children's Oncology Group Trials","author":"Zhou R","year":"2016","journal-title":"Int J Radiat Oncol Biol"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2014.05.003"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.05.005"},{"key":"e_1_2_6_9_1","unstructured":"Castellino SM. Children's Oncology Group AHOD1331: a randomized phase 3 study of brentuximab vedotin (SGN\u201035 IND#117117) for newly diagnosed high\u2010risk classical Hodgkin lymphoma (cHL) in children and young adults. June2017:1\u2010181."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20546"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24279"},{"key":"e_1_2_6_12_1","first-page":"1","volume-title":"Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB\/IVB) (AHOD0831): A Report from the Children's Oncology Group","author":"Kelly KM","year":"2015"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26278"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-285379"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1026870"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199001043220102"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22664"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.2.312"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3736"},{"issue":"1","key":"e_1_2_6_20_1","first-page":"181","article-title":"Individualisation of radiation fields based on modern sectional imaging within combination treatment of pediatric Hodgkin's disease (HD): evaluation of 386 patients from the German\u2010Austrian multicenter trial (HD\u201090)","volume":"32","author":"P\u00f6tter R","year":"2020","journal-title":"Int J Radiat Oncol Biol"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.301.6760.1077"},{"key":"e_1_2_6_22_1","unstructured":"ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016 Feb 18 - Identifier NCT02684708 Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents; 2016 Feb 18 [cited 2019 Apr 22]; [about 8 screens]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02684708."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1354416"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2017.01.001"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2715-9"},{"issue":"5","key":"e_1_2_6_26_1","first-page":"35","article-title":"First international inter\u2010group study for classical Hodgkin lymphoma in children and adolescents: euroNet\u2010PHL\u2010C1. Report of the latest interim analysis","volume":"101","author":"Landman\u2010Parker J","year":"2016","journal-title":"Haematologica"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9381"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.3288"},{"key":"e_1_2_6_29_1","first-page":"1","article-title":"Secondary malignancies following treatment for Hodgkin's lymphoma in childhood and adolescence","author":"D\u00f6rffel W","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.059"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.09.012"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.12.034"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595801"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.28562","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.28562","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.28562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T16:57:13Z","timestamp":1692982633000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.28562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":37,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/pbc.28562"],"URL":"https:\/\/doi.org\/10.1002\/pbc.28562","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"2020-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e28562"}}